During the last session, Ampio Pharmaceuticals Inc. (AMEX:AMPE)’s traded shares were 2.21 million, with the beta value of the company hitting 1.84. At the end of the trading day, the stock’s price was $0.21, reflecting an intraday gain of 5.59% or $0.01. The 52-week high for the AMPE share is $2.00, that puts it down -852.38 from that peak though still a striking 4.76% gain since the share price plummeted to a 52-week low of $0.20. The company’s market capitalization is $51.18M, and the average trade volume was 2.92 million shares over the past three months.
Ampio Pharmaceuticals Inc. (AMPE) received a consensus recommendation of a Buy from analysts. That translates to a mean rating of 2.00. AMPE has a Sell rating from 0 analyst(s) out of 2 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 2 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -$0.02.
Ampio Pharmaceuticals Inc. (AMEX:AMPE) trade information
Ampio Pharmaceuticals Inc. (AMPE) registered a 5.59% upside in the last session and has traded in the red over the past 5 sessions. The stock spiked 5.59% in intraday trading to $0.21 this Thursday, 05/12/22, hitting a weekly high. The stock’s 5-day price performance is -12.54%, and it has moved by -46.10% in 30 days. Based on these gigs, the overall price performance for the year is -88.27%.
The consensus price target of analysts on Wall Street is $2.50, which implies an increase of 91.6% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $2.00 and $3.00 respectively. As a result, AMPE is trading at a discount of -1328.57% off the target high and -852.38% off the low.
Ampio Pharmaceuticals Inc. (AMPE) estimates and forecasts
Statistics show that Ampio Pharmaceuticals Inc. has outperformed its competitors in share price, compared to the industry in which it operates. Ampio Pharmaceuticals Inc. (AMPE) shares have gone down -86.14% during the last six months, with a year-to-date growth rate more than the industry average at 10.00% against 9.70.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 24.80%. While earnings are projected to return 6.80% in 2022.
Ampio Pharmaceuticals Inc. is due to release its next quarterly earnings between August 02 and August 08. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Ampio Pharmaceuticals Inc. (AMEX:AMPE)’s Major holders
Ampio Pharmaceuticals Inc. insiders own 7.98% of total outstanding shares while institutional holders control 26.98%, with the float percentage being 29.32%. Blackrock Inc. is the largest shareholder of the company, while 162 institutions own stock in it. As of Dec 30, 2021, the company held over 13.93 million shares (or 6.13% of all shares), a total value of $7.94 million in shares.
The next largest institutional holding, with 9.23 million shares, is of Vanguard Group, Inc. (The)’s that is approximately 4.06% of outstanding shares. At the market price on Dec 30, 2021, these shares were valued at $5.26 million.
Also, the Mutual Funds coming in first place with the largest holdings of Ampio Pharmaceuticals Inc. (AMPE) shares are Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF. Data provided on Dec 30, 2021 indicates that Vanguard Total Stock Market Index Fund owns about 5.25 million shares. This amounts to just over 2.31 percent of the company’s overall shares, with a $2.99 million market value. The same data shows that the other fund manager holds slightly less at 4.42 million, or about 1.94% of the stock, which is worth about $2.29 million.